iTeos Therapeutics, Inc. Common Stock
Compare this stock
ITOS Stock Report Card
$
28%
Performance
Score:
10/100
ITOS returned -55.33% in the last 12 months. Based on SPY's performance of 476.36%, its performance is below average giving it a score of 10 of 100.
Sentiment
Score:
72/100
ITOS had a bullish sentiment score of 71.97% across Twitter and StockTwits over the last 12 months. It had an average of 2.33 posts, 2.67 comments, and 4.00 likes per day.
Technicals
Score:
14/100
ITOS receives a 14 of 100 based on 14 indicators. 1 are bullish, 11 are bearish.
Earnings
Score:
10/100
ITOS has missed earnings 5 times in the last 20 quarters.
Profit
Score:
31/100
Out of the last 19 quarters, ITOS has had 6 profitable quarters and has increased their profits year over year on 4 of them.
Volatility
Score:
40/100
ITOS has had a lower than average amount of volatility over the last 12 months giving it a score of 40 of 100.
iTeos Therapeutics, Inc. Common Stock Summary
Nasdaq / ITOS
Healthcare
Biotechnology
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Checkout Similar Companies
ITOS scored poorly on our reportcard. Here are some similar companies and how they performed.
